IO360° Summit

Elliot Norry, MD, FACP, CMO, Adaptimmune LLC

9:10AM - 9:35AM

Keynote: CAR-T in Autoimmune Diseases

Prof. Dr. Georg Schett, VP Research FAU and Head of Department of Medicine 3 – Rheumatology and Immunology, Uniklinikum Erlangen and FAU Erlangen-Nürnberg

9:35AM - 10:10AM

Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies

Moderator:

Priti Hegde, PhD, SVP and Global Head of Research, Kite Pharma, a Gilead Company

Panelists:

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies

Rachel Humphrey, MD, President and Founding CEO, Normunity

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Showing Events in 1 Track from 10:10am to 10:50am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

10:10AM - 10:50AM

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 10:50am to 11:30am

Track 1

PRAME TCR-Ts for Solid Tumors

Delfi Krishna, PhD, VP, Strategic Operations, Immatics Biotechnologies

Bispecifics: The Next Generation of CTLA-4 and PD1 Inhibition

John Kurland, PhD, VP, Global Product Leader IO - GI and Head and Neck Cancers, AstraZeneca

Track 2

Clinical and Translational Learnings During Development of Abecma - The First Approved Myeloma CAR -T Cell Therapy

Timothy Campbell, MD, PhD, VP, Hematology and Cell Therapy, Early Clinical Development, BMS

CHS-114: A Highly Selective Cytolytic CCR8 Monoclonal Antibody Treatment in HNSCC Patients with and without Toripalimab

Varun Kapoor, PhD, Senior Director, Translational Medicine, Coherus Biosciences

Showing Events in 1 Track from 12:10pm to 01:10pm

Lunch

12:10PM - 1:10PM

Lunch on Own & 1:1 Partnering Meetings

Showing Events in 1 Track from 01:10pm to 03:00pm

IO Clinical Advancements Plenary (Continued)

1:10PM - 1:30PM

Neoadjuvant Immunotherapy Clinical Developments in Multiple Tumor Types

Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

1:30PM - 2:00PM

Advancing Cancer Vaccines and Neoantigen Therapies: Current Breakthroughs and Strategic Pathways

Led By:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

2:00PM - 2:20PM

Clinical Updates on CD226

2:20PM - 2:40PM

Progress Update on TCR-Targeted Bispecific Antibody Monotherapy in Anti-PD(L)1-Resistant Solid Tumors: Phase 1/2 Study Findings

Zhen Su, MD, MBA, CEO & Director, Marengo Therapeutics

2:40PM - 3:00PM

Solid Tumor CD3 Redirectors

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

Showing Events in 1 Track from 03:40pm to 03:45pm

End of Conference

3:40PM - 3:45PM

End of Conference

Showing Events in 1 Track from 08:00am to 10:10am

IO Clinical Advancements Plenary

8:00AM - 8:30AM

Registration & 1:1 Partnering Meetings

8:35AM - 8:45AM

Day Three Welcome

8:45AM - 9:10AM

Keynote: Adaptimmune's Pioneering TCR-Based Cell Therapy - Transforming Treatment for Solid Tumors

Elliot Norry, MD, FACP, CMO, Adaptimmune LLC

9:10AM - 9:35AM

Keynote: CAR-T in Autoimmune Diseases

Prof. Dr. Georg Schett, VP Research FAU and Head of Department of Medicine 3 – Rheumatology and Immunology, Uniklinikum Erlangen and FAU Erlangen-Nürnberg

9:35AM - 10:10AM

Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies

Moderator:

Priti Hegde, PhD, SVP and Global Head of Research, Kite Pharma, a Gilead Company

Panelists:

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies

Rachel Humphrey, MD, President and Founding CEO, Normunity

Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences

Showing Events in 1 Track from 10:10am to 10:50am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

10:10AM - 10:50AM

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 10:50am to 11:30am

Track 1

PRAME TCR-Ts for Solid Tumors

Delfi Krishna, PhD, VP, Strategic Operations, Immatics Biotechnologies

Bispecifics: The Next Generation of CTLA-4 and PD1 Inhibition

John Kurland, PhD, VP, Global Product Leader IO - GI and Head and Neck Cancers, AstraZeneca

Track 2

Clinical and Translational Learnings During Development of Abecma - The First Approved Myeloma CAR -T Cell Therapy

Timothy Campbell, MD, PhD, VP, Hematology and Cell Therapy, Early Clinical Development, BMS

CHS-114: A Highly Selective Cytolytic CCR8 Monoclonal Antibody Treatment in HNSCC Patients with and without Toripalimab

Varun Kapoor, PhD, Senior Director, Translational Medicine, Coherus Biosciences

Showing Events in 1 Track from 12:10pm to 01:10pm

Lunch

12:10PM - 1:10PM

Lunch on Own & 1:1 Partnering Meetings

Showing Events in 1 Track from 01:10pm to 03:00pm

IO Clinical Advancements Plenary (Continued)

1:10PM - 1:30PM

Neoadjuvant Immunotherapy Clinical Developments in Multiple Tumor Types

Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

1:30PM - 2:00PM

Advancing Cancer Vaccines and Neoantigen Therapies: Current Breakthroughs and Strategic Pathways

Led By:

Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna

2:00PM - 2:20PM

Clinical Updates on CD226

2:20PM - 2:40PM

Progress Update on TCR-Targeted Bispecific Antibody Monotherapy in Anti-PD(L)1-Resistant Solid Tumors: Phase 1/2 Study Findings

Zhen Su, MD, MBA, CEO & Director, Marengo Therapeutics

2:40PM - 3:00PM

Solid Tumor CD3 Redirectors